

# Jochen Reiser

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/808963/jochen-reiser-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92  
papers

4,692  
citations

30  
h-index

68  
g-index

105  
ext. papers

5,769  
ext. citations

10.6  
avg, IF

5.23  
L-index

#	Paper	IF	Citations
92	Overriding impaired FPR chemotaxis signaling in diabetic neutrophil stimulates infection control in murine diabetic wound.. <i>ELife</i> , <b>2022</b> , 11,	8.9	3
91	Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte $\beta$ Integrin.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 68-77	4.1	0
90	Crkl/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by <i>Pseudomonas aeruginosa</i> ExoT.. <i>Nature Communications</i> , <b>2022</b> , 13, 1295	17.4	0
89	Therapeutic evaluation of immunomodulators in reducing surgical wound infection.. <i>FASEB Journal</i> , <b>2022</b> , 36, e22090	0.9	1
88	Refining colorectal cancer classification and clinical stratification through a single-cell atlas.. <i>Genome Biology</i> , <b>2022</b> , 23, 113	18.3	2
87	Simultaneous stabilization of actin cytoskeleton in multiple nephron-specific cells protects the kidney from diverse injury.. <i>Nature Communications</i> , <b>2022</b> , 13, 2422	17.4	0
86	Assay-related differences in SuPAR levels: implications for measurement and data interpretation.. <i>Journal of Nephrology</i> , <b>2022</b> , 1	4.8	
85	Soluble Urokinase Plasminogen Activator Receptor Is Associated With Subclinical Myocardial Impairment by Speckle Tracking Echocardiography in Lung Cancer Patients.. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 659524	5.4	
84	suPAR, a Circulating Kidney Disease Factor. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 745838	4.9	0
83	Application of regularized regression to identify novel predictors of mortality in a cohort of hemodialysis patients. <i>Scientific Reports</i> , <b>2021</b> , 11, 9287	4.9	
82	<i>Pseudomonas aeruginosa</i> ExoT induces G1 cell cycle arrest in melanoma cells. <i>Cellular Microbiology</i> , <b>2021</b> , 23, e13339	3.9	5
81	Comparative incidence and outcomes of COVID-19 in kidney or kidney-pancreas transplant recipients versus kidney or kidney-pancreas waitlisted patients: A single-center study. <i>Clinical Transplantation</i> , <b>2021</b> , 35, e14362	3.8	2
80	Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 208-221	14.5	44
79	Guanidinylated Apolipoprotein C3 (ApoC3) Associates with Kidney and Vascular Injury. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2021</b> ,	12.7	6
78	IL-10 Dysregulation Underlies Chemokine Insufficiency, Delayed Macrophage Response, and Impaired Healing in Diabetic Wound. <i>Journal of Investigative Dermatology</i> , <b>2021</b> ,	4.3	4
77	Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. <i>Critical Care</i> , <b>2020</b> , 24, 187	10.8	70
76	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 1119-1128	11.5	65

75	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. <i>Nature Immunology</i> , <b>2020</b> , 21, 30-41	19.1	78
74	Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 2725-2735	12.7	45
73	Podocyte Integrin- and Activated Protein C Coordinately Restrict RhoA Signaling and Ameliorate Diabetic Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2020</b> , 31, 1762-1780	12.7	5
72	Glomerular filtration barrier dysfunction in a self-limiting, RNA virus-induced glomerulopathy resembles findings in idiopathic nephrotic syndromes. <i>Scientific Reports</i> , <b>2020</b> , 10, 19117	4.9	4
71	Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> , 35, 465-470	4.3	8
70	Percutaneous Renal Biopsy Using an 18-Gauge Automated Needle Is Not Optimal. <i>American Journal of Nephrology</i> , <b>2020</b> , 51, 982-987	4.6	2
69	Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. <i>Scientific Reports</i> , <b>2019</b> , 9, 475	4.9	4
68	MeSsAGe risk score: tool for renal biopsy decision in steroid-dependent nephrotic syndrome. <i>Pediatric Research</i> , <b>2019</b> , 85, 477-483	3.2	1
67	Soluble Urokinase Plasminogen Activator Receptor and Decline in Kidney Function in Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1305-1313	12.7	14
66	Wnt signaling in bone, kidney, intestine, and adipose tissue and interorgan interaction in aging. <i>Annals of the New York Academy of Sciences</i> , <b>2019</b> , 1442, 48-60	6.5	27
65	Contribution of Coiled-Coil Assembly to Ca/Calmodulin-Dependent Inactivation of TRPC6 Channel and its Impacts on FSGS-Associated Phenotypes. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2019</b> , 30, 1587-1603	12.7	12
64	Nonimmune cell-derived ICOS ligand functions as a renoprotective $\alpha\beta$ integrin-selective antagonist. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1713-1726	15.9	11
63	uPAR isoform 2 forms a dimer and induces severe kidney disease in mice. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 1946-1959	15.9	29
62	Cell Cycle Biomarkers and Soluble Urokinase-Type Plasminogen Activator Receptor for the Prediction of Sepsis-Induced Acute Kidney Injury Requiring Renal Replacement Therapy: A Prospective, Exploratory Study. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e999-e1007	1.4	5
61	Podocytes: Way to Go. <i>American Journal of Pathology</i> , <b>2019</b> , 189, 226-228	5.8	4
60	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 676-686	11.6	33
59	More expression, less function: cleaved dynamin in glomerular kidney disease. <i>Journal of Pathology</i> , <b>2019</b> , 247, 413-415	9.4	2
58	Single-nephron proteomes connect morphology and function in proteinuric kidney disease. <i>Kidney International</i> , <b>2018</b> , 93, 1308-1319	9.9	32

57	High-content screening assay-based discovery of paullones as novel podocyte-protective agents. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, F280-F292	4.3	7
56	TRPC5 Does Not Cause or Aggravate Glomerular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 409-415	12.7	29
55	Podocytes exhibit a specialized protein quality control employing derlin-2 in kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, F471-F482	4.3	4
54	Motility of human renal cells is disturbed by infection with pathogenic hantaviruses. <i>BMC Infectious Diseases</i> , <b>2018</b> , 18, 645	4	8
53	Stop TRPC5 in Kidney Disease: A Game Changer for Renal Allograft Protection?. <i>Transplantation</i> , <b>2018</b> , 102, 1027-1029	1.8	1
52	Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. <i>BMC Nephrology</i> , <b>2018</b> , 19, 361	2.7	10
51	Kidney-derived c-kit progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuria. <i>Scientific Reports</i> , <b>2018</b> , 8, 14723	4.9	11
50	Renal Dysfunction and Recovery following Initial Treatment of Newly Diagnosed Multiple Myeloma. <i>International Journal of Nephrology</i> , <b>2018</b> , 2018, 4654717	1.7	4
49	Fetal Renal Echogenicity Associated with Maternal Focal Segmental Glomerulosclerosis: The Effect of Transplacental Transmission of Permeability Factor suPAR. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,	5.1	3
48	Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients. <i>Kidney International Reports</i> , <b>2018</b> , 3, 1100-1109	4.1	9
47	Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 1013-1021	6.9	15
46	Targeting mTOR Signaling Can Prevent the Progression of FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 2144-2157	12.7	35
45	Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. <i>Kidney International Reports</i> , <b>2017</b> , 2, 425-432	4.1	16
44	A High-Content Screening Technology for Quantitatively Studying Podocyte Dynamics. <i>Advances in Chronic Kidney Disease</i> , <b>2017</b> , 24, 183-188	4.7	4
43	Apoptosis and Compensatory Proliferation Signaling Are Coupled by Crkl-Containing Microvesicles. <i>Developmental Cell</i> , <b>2017</b> , 41, 674-684.e5	10.2	27
42	Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. <i>Nature Medicine</i> , <b>2017</b> , 23, 100-106	50.5	89
41	Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus. <i>Journal of Diabetes Research</i> , <b>2017</b> , 2017, 3232848	3.9	23
40	Unwinding focal segmental glomerulosclerosis. <i>F1000Research</i> , <b>2017</b> , 6, 466	3.6	19

39	Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. <i>JAMA Pediatrics</i> , <b>2017</b> , 171, e172914	8.3	32
38	Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. <i>Atherosclerosis</i> , <b>2017</b> , 264, 108-114	3.1	16
37	A tripartite complex of suPAR, APOL1 risk variants and $\alpha$ 5 $\beta$ 1 Integrin on podocytes mediates chronic kidney disease. <i>Nature Medicine</i> , <b>2017</b> , 23, 945-953	50.5	121
36	suPAR and chronic kidney disease-a podocyte story. <i>Pflugers Archiv European Journal of Physiology</i> , <b>2017</b> , 469, 1017-1020	4.6	24
35	Extrarenal determinants of kidney filter function. <i>Cell and Tissue Research</i> , <b>2017</b> , 369, 211-216	4.2	2
34	Dynamin Autonomously Regulates Podocyte Focal Adhesion Maturation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2017</b> , 28, 446-451	12.7	18
33	Podocyte Purinergic P2X4 Channels Are Mechanotransducers That Mediate Cytoskeletal Disorganization. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 848-62	12.7	27
32	We Wait Too Long to Refer Patients for Transplantation. <i>Seminars in Dialysis</i> , <b>2016</b> , 29, 318-9	2.5	3
31	Podocytes. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	100
30	Synaptopodin Limits TRPC6 Podocyte Surface Expression and Attenuates Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 3308-3319	12.7	30
29	Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 2259-66	12.7	113
28	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 1443-8	12.7	86
27	A Podocyte-Based Automated Screening Assay Identifies Protective Small Molecules. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2015</b> , 26, 2741-52	12.7	44
26	Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid. <i>Frontiers in Medicine</i> , <b>2015</b> , 2, 10	4.9	6
25	Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. <i>Nature Medicine</i> , <b>2015</b> , 21, 601-9	50.5	84
24	Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. <i>BMC Nephrology</i> , <b>2015</b> , 16, 111	2.7	50
23	Soluble Urokinase Receptor and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1916-25	59.2	248
22	CD2AP, dendrin, and cathepsin L in the kidney. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 3129-30	5.8	4

21	In vivo imaging and characterization of actin microridges. <i>PLoS ONE</i> , <b>2015</b> , 10, e0115639	3.7	30
20	A case report of adrenocorticotrophic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoring. <i>Frontiers in Medicine</i> , <b>2015</b> , 2, 13	4.9	7
19	Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte $\beta$ -integrin Activation. <i>Transplantation</i> , <b>2015</b> , 99, 2593-7	1.8	28
18	Circulating CD40 autoantibody and suPAR synergy drives glomerular injury. <i>Annals of Translational Medicine</i> , <b>2015</b> , 3, 300	3.2	8
17	Proteinuria: abate or applaud abatacept in proteinuric kidney disease?. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 128-30	14.9	10
16	Signal transduction in podocytes--spotlight on receptor tyrosine kinases. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 104-15	14.9	21
15	Reduction of proteinuria through podocyte alkalinization. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 17454-67	5.4	10
14	MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1698-709	12.7	132
13	In vivo imaging of kidney glomeruli transplanted into the anterior chamber of the mouse eye. <i>Scientific Reports</i> , <b>2014</b> , 4, 3872	4.9	18
12	Reassessing the Reassessment of suPAR in Glomerular Disease. <i>Frontiers in Medicine</i> , <b>2014</b> , 1, 59	4.9	5
11	Role of podocyte B7-1 in diabetic nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1415-29	12.7	92
10	A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 256ra136	17.5	138
9	Structure of the kidney slit diaphragm adapter protein CD2-associated protein as determined with electron microscopy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 1465-73	12.7	4
8	Podocyte biology and pathogenesis of kidney disease. <i>Annual Review of Medicine</i> , <b>2013</b> , 64, 357-66	17.4	141
7	Circulating permeability factor suPAR: from concept to discovery to clinic. <i>Transactions of the American Clinical and Climatological Association</i> , <b>2013</b> , 124, 133-8	0.9	10
6	Circulating suPAR in two cohorts of primary FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2012</b> , 23, 2051-9	12.7	171
5	Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. <i>Nature Medicine</i> , <b>2011</b> , 17, 952-60	50.5	619
4	CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 3965-80	15.9	106

3	The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. <i>Nature Medicine</i> , <b>2008</b> , 14, 931-8	50.5	708
2	Modification of kidney barrier function by the urokinase receptor. <i>Nature Medicine</i> , <b>2008</b> , 14, 55-63	50.5	410
1	Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 2095-104	15.9	162